Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Antibiotic study will take 18 months to complete, Pfizer says.

Related Content

In Another Pfizer Fire Sale, VC-Backed Conatus Acquires Idun's Idle Assets
FDA Shows When And How To Use, Or Not To Use, Non-Inferiority Trials
Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance
FDA Updating Antibiotic Guidances, But Is It Too Late For Some Sponsors?
Antibiotic Non-Inferiority Trials To Be Addressed By FDA Advisory Committee
J&J/Basilea’s Ceftobiprole NDA Edges Ahead
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin
Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin
Pfizer Expands Anti-Infective Portfolio With $1.9 Bil. Vicuron Acquisition





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts